Company / Shareholders' Equity
Arcadia Biosciences, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$6.2M
FY2025
5-year range
$6.2M / $31.1M
FY2021-FY2025
Trend
-51.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 4 consecutive years, from $31M in FY2021 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -25.8%.
Declined from $13M to $6M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -33.4%
- 5-Year CAGR
- -25.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of -25.8%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 51.0% year-over-year.
- Peak shareholders' equity was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.2M | -51.0% |
| FY2024 | $12.7M | -1.1% |
| FY2023 | $12.8M | -38.9% |
| FY2022 | $21.0M | -32.4% |
| FY2021 | $31.1M | +12.1% |
| FY2020 | $27.7M | +259.8% |
| FY2019 | $7.7M | -3.8% |
| FY2018 | $8.0M | -63.9% |
| FY2017 | $22.2M | -44.8% |
| FY2016 | $40.2M | +147.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026